Use of tremonorm in treatment of Parkinson's disease: Outpatient experience of moscow municipal health care service

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 104, Issue 12, 2004, Pages 23-28

  Boiko, A N ^a   Batysheva, T T ^a   Chikina, E S ^a   Artemova, I Y ^a   Vdovichenko, T V ^a   Ganzhula, P A ^a   Ismailov, A M ^a   Lisenker, L N ^a   Obydenova, N A ^a   Rotor, L D ^a   Khozova, A A ^a   Vinetsky, Y Y ^a  

^a NONE

Author keywords

Parkinson's disease; Therapy; Tremonorm

Indexed keywords

CARBIDOPA; LEVODOPA;

ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; DYSPEPSIA; ECONOMICS; HUMAN; MENTAL HEALTH; OUTPATIENT; PARKINSON DISEASE; QUALITY OF LIFE; QUESTIONNAIRE; RUSSIAN FEDERATION; STATISTICAL ANALYSIS; TIME; TREATMENT OUTCOME;

CARBIDOPA; DATA INTERPRETATION, STATISTICAL; DRUG COMBINATIONS; DYSPEPSIA; HUMANS; LEVODOPA; MENTAL STATUS SCHEDULE; MOSCOW; OUTPATIENTS; PARKINSON DISEASE; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 18244384502     PISSN: 19977298     EISSN: 19977298     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. CONTINUUM. A programm of the American Academy of Neurology. Parkinson's Disease 1995; 1: 4: 1-169.
2. Fahn S., Elton R.L., members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Recent developments in Parkinson's disease. In: S. Fahn, CD. Marsden, D.B. Calne et al. (eds.). Florham Park, NJ: MacMillan Health Care Information 1987; 153-163.
3. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the mental state of patients for the clinicians. J Psychiat Res 1975; 12: 189-198.
4. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
5. Jenkinson C, Fitzpatrick R., Norquist J. et al. Cross-cultural evaluation of the Parkinson's Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain. J Clin Epidemiol 2003; 56: 9: 843-847.
6. Martinez-Martin P. Conversion to controlled-release levodopa/carbi-dopa treatment and quality of life as measured by the Nottingham Health Profile. The STAR Study Group. Neurology 1999; 14: 338-343.
7. Obesso J.A., Rodriguez-Oroz M.C, Rodriguez M. et al. Pathophysioli-gy of the basal ganglia in Parkinson's disease. Trends Neurosc 2000; 23: 8-19.
8. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56: Suppl 5: 1-88.
9. Peto V., Jenkinson C, Fitzpatrick R., Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4: 241-248.
10. Peto V., Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's Disease Questionnaire. Age Ageing 2001; 30: 299-302.
11. Waters C.H. Diagnosis and management of Parkinson's disease. 2002; 1-240.